148 related articles for article (PubMed ID: 12025961)
1. Bradykinin-related compounds as new drugs for cancer and inflammation.
Stewart JM; Gera L; Chan DC; Bunn PA; York EJ; Simkeviciene V; Helfrich B
Can J Physiol Pharmacol; 2002 Apr; 80(4):275-80. PubMed ID: 12025961
[TBL] [Abstract][Full Text] [Related]
2. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
Chan DC; Gera L; Stewart JM; Helfrich B; Zhao TL; Feng WY; Chan KK; Covey JM; Bunn PA
Clin Cancer Res; 2002 May; 8(5):1280-7. PubMed ID: 12006549
[TBL] [Abstract][Full Text] [Related]
3. Combination cancer chemotherapy with one compound: pluripotent bradykinin antagonists.
Stewart JM; Gera L; Chan DC; York EJ; Simkeviciene V; Bunn PA; Taraseviciene-Stewart L
Peptides; 2005 Aug; 26(8):1288-91. PubMed ID: 15878795
[TBL] [Abstract][Full Text] [Related]
4. Potent, long-acting bradykinin antagonists for a wide range of applications.
Stewart JM; Gera L; Chan DC; Whalley ET; Hanson WL; Zuzack JS
Can J Physiol Pharmacol; 1997 Jun; 75(6):719-24. PubMed ID: 9276154
[TBL] [Abstract][Full Text] [Related]
5. Structural modification of the highly potent peptide bradykinin B1 receptor antagonist B9958.
Gera L; Stewart JM; Fortin JP; Morissette G; Marceau F
Int Immunopharmacol; 2008 Feb; 8(2):289-92. PubMed ID: 18182242
[TBL] [Abstract][Full Text] [Related]
6. A new generation of bradykinin antagonists.
Stewart JM; Gera L; Hanson W; Zuzack JS; Burkard M; McCullough R; Whalley ET
Immunopharmacology; 1996 Jun; 33(1-3):51-60. PubMed ID: 8856115
[TBL] [Abstract][Full Text] [Related]
7. Correlation of secondary structures of bradykinin B1 receptor antagonists with their activity.
Miskolzie M; Gera L; Stewart JM; Kotovych G
J Biomol Struct Dyn; 2002 Feb; 19(4):585-93. PubMed ID: 11843620
[TBL] [Abstract][Full Text] [Related]
8. In various tumour cell lines the peptide bradykinin B(2) receptor antagonist, Hoe 140 (Icatibant), may act as mitogenic agonist.
Drube S; Liebmann C
Br J Pharmacol; 2000 Dec; 131(8):1553-60. PubMed ID: 11139431
[TBL] [Abstract][Full Text] [Related]
9. Agonist activity at the kinin B1 receptor: structural requirements of the central tetrapeptide.
Rovero P; Pellegrini M; Di Fenza A; Meini S; Quartara L; Maggi CA; Formaggio F; Toniolo C; Mierke DF
J Med Chem; 2001 Jan; 44(2):274-8. PubMed ID: 11170638
[TBL] [Abstract][Full Text] [Related]
10. LC/MS characterization of impurities and degradation products of a potent antitumor peptidic dimer, CU201.
Wang J; Krishnamoorthi V; Wang E; Yang C; Baptista D; Wu X; Liu M; Gardner M; Elkins P; Hines J; Liu P
J Pharm Biomed Anal; 2010 Mar; 51(4):824-33. PubMed ID: 19897331
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of canine bradykinin receptors in prostatic culture and in isolated prostate.
Srinivasan D; Burbach LR; Daniels DV; Ford AP; Bhattacharya A
Br J Pharmacol; 2004 May; 142(2):297-304. PubMed ID: 15155537
[TBL] [Abstract][Full Text] [Related]
12. Bradykinin receptor antagonists containing N-substituted amino acids: in vitro and in vivo B(2) and B(1) receptor antagonist activity.
Goodfellow VS; Marathe MV; Kuhlman KG; Fitzpatrick TD; Cuadrado D; Hanson W; Zuzack JS; Ross SE; Wieczorek M; Burkard M; Whalley ET
J Med Chem; 1996 Mar; 39(7):1472-84. PubMed ID: 8691478
[TBL] [Abstract][Full Text] [Related]
13. Peptide and non-peptide bradykinin B2 receptor agonists and antagonists: a reappraisal of their pharmacology in the guinea-pig ileum.
Meini S; Patacchini R; Lecci A; Quartara L; Maggi CA
Eur J Pharmacol; 2000 Dec; 409(2):185-94. PubMed ID: 11104833
[TBL] [Abstract][Full Text] [Related]
14. Potent, long-acting, orally-active bradykinin antagonists for a wide range of applications.
Stewart JM; Gera L; Chan DC; Whalley ET; Hanson WL; Zuzack JS
Immunopharmacology; 1997 Jun; 36(2-3):167-72. PubMed ID: 9228542
[TBL] [Abstract][Full Text] [Related]
15. [Arg6,D-Trp7,9,NmePhe8]-substance P (6-11) activates JNK and induces apoptosis in small cell lung cancer cells via an oxidant-dependent mechanism.
MacKinnon AC; Armstrong RA; Waters CM; Cummings J; Smyth JF; Haslett C; Sethi T
Br J Cancer; 1999 Jun; 80(7):1026-34. PubMed ID: 10362111
[TBL] [Abstract][Full Text] [Related]
16. The neurotoxin 1-methyl-4-phenylpyridinium: a selective cytostatic agent in small-cell lung cancer cell lines with neuroendocrine properties.
Marini AM; Fridman R; Kanemoto T; Martin GR; Guo Y; Passaniti A
J Natl Cancer Inst; 1992 Oct; 84(20):1582-7. PubMed ID: 1328660
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a novel binding site for 125I-Tyr-D-Arg-[Hyp3,D-Phe7,Leu8]bradykinin on epithelial membranes of guinea pig ileum.
Tousignant C; Regoli D; Rhaleb NE; Jukic D; Guillemette G
Eur J Pharmacol; 1992 Mar; 225(3):235-44. PubMed ID: 1325366
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the contractile action of bradykinin on isolated smooth muscle preparations by derivatives of low molecular weight peptides.
Claeson G; Fareed J; Larsson C; Kindel G; Arielly S; Simonsson R; Messmore HL; Balis JU
Adv Exp Med Biol; 1979; 120B():691-713. PubMed ID: 517262
[TBL] [Abstract][Full Text] [Related]
19. MEN 11270, A novel selective constrained peptide antagonist with high affinity at the human B2 kinin receptor.
Meini S; Quartara L; Rizzi A; Patacchini R; Cucchi P; Giolitti A; Calò G; Regoli D; Criscuoli M; Maggi CA
J Pharmacol Exp Ther; 1999 Jun; 289(3):1250-6. PubMed ID: 10336513
[TBL] [Abstract][Full Text] [Related]
20. Strong cytotoxic effect of the bradykinin antagonist BKM-570 in ovarian cancer cells--analysis of the molecular mechanisms of its antiproliferative action.
Jutras S; Bachvarova M; Keita M; Bascands JL; Mes-Masson AM; Stewart JM; Gera L; Bachvarov D
FEBS J; 2010 Dec; 277(24):5146-60. PubMed ID: 21078129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
